Madaus Martin D — SEC insider filings
SEC reporting owner CIK 1310268. 44 insider filings on record with FilingPulse; latest filed 2026-10-23.
Transaction summary — filings shown
Covers all 44 filings on record, filed 2020-08-20 to 2026-10-23. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 9 legs across 6 filings — 104,967 shares, $1,899,573 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 15 legs across 7 filings — 22,172 shares, $812,303 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 82.
- Largest priced transaction: purchase of 89,667 shares @ $8.43 ($755,543) in Quanterix Corp, filed 2022-08-10.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Quanterix Corp (QTRX) | Director | 17 | 1 leg · 89,667 sh · $755,543 | 15 legs · 22,172 sh · $812,303 | 47 |
| REPLIGEN CORP (RGEN) | Director | 8 | 6 legs · 4,915 sh · $641,866 | — | 12 |
| HOLOGIC INC (HOLX) | Director | 5 | 1 leg · 5,445 sh · $300,760 | — | 8 |
| Azenta, Inc. (AZTA) | Interim CEO | 8 | 1 leg · 4,940 sh · $201,404 | — | 6 |
| STANDARD BIOTOOLS INC. (LAB) | Director | 5 | — | — | 8 |
| HAEMONETICS CORP (HAE) | Director | 1 | — | — | 1 |
Insider filings — Madaus Martin D
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-23 | 4 | Azenta, Inc. (AZTA) | Tax withholding (F): 1,294 @ $36.01 | EDGAR |
| 2026-09-23 | 4 | Azenta, Inc. (AZTA) | Tax withholding (F): 1,456 @ $34.28 | EDGAR |
| 2026-09-16 | 4 | Azenta, Inc. (AZTA) | Grant/award (A): 36,653 @ $0 | EDGAR |
| 2026-07-28 | 4 | HAEMONETICS CORP (HAE) | Grant/award (A): 2,538 | EDGAR |
| 2026-05-18 | 4 | REPLIGEN CORP (RGEN) | Grant/award (A): 995 @ $0 · Grant/award (A): 2,239 (derivative) @ $0 | EDGAR |
| 2026-04-09 | 4 | HOLOGIC INC (HOLX) | Disposition to issuer (D): 5,396 · Disposition to issuer (D): 5,445 · Disposition to issuer (D): 1,016 (derivative) · Disposition to issuer (D): 5,535 (derivative) | EDGAR |
| 2026-03-02 | 4 | HOLOGIC INC (HOLX) | Grant/award (A): 3,190 | EDGAR |
| 2026-02-06 | 4 | Azenta, Inc. (AZTA) | Grant/award (A): 5,663 (derivative) | EDGAR |
| 2025-11-25 | 4/A | Azenta, Inc. (AZTA) | Holdings only — no transactions reported | EDGAR |
| 2025-08-12 | 4 | REPLIGEN CORP (RGEN) | Purchase (P): 1,800 @ $112.13 | EDGAR |
| 2025-05-19 | 4 | REPLIGEN CORP (RGEN) | Grant/award (A): 973 @ $0 · Grant/award (A): 1,800 (derivative) @ $0 | EDGAR |
| 2025-05-09 | 4 | HOLOGIC INC (HOLX) | Purchase (P): 5,445 @ $55.24 | EDGAR |
| 2025-02-28 | 4 | HOLOGIC INC (HOLX) | Grant/award (A): 1,864 · Grant/award (A): 5,535 (derivative) @ $0 | EDGAR |
| 2025-02-11 | 4 | Azenta, Inc. (AZTA) | Grant/award (A): 4,040 (derivative) | EDGAR |
| 2025-01-06 | 4 | Quanterix Corp (QTRX) | Grant/award (A): 7,435 @ $0 · Grant/award (A): 15,821 (derivative) @ $0 | EDGAR |
| 2024-12-11 | 4 | HOLOGIC INC (HOLX) | Grant/award (A): 342 | EDGAR |
| 2024-11-19 | 4 | Azenta, Inc. (AZTA) | Purchase (P): 4,940 @ $40.77 | EDGAR |
| 2024-06-14 | 4 | REPLIGEN CORP (RGEN) | Purchase (P): 915 @ $124.54 · Purchase (P): 700 @ $125.46 | EDGAR |
| 2024-05-20 | 4 | REPLIGEN CORP (RGEN) | Grant/award (A): 701 @ $0 · Grant/award (A): 1,376 (derivative) @ $0 | EDGAR |
| 2024-02-13 | 4 | Azenta, Inc. (AZTA) | Grant/award (A): 2,465 @ $65.93 | EDGAR |
| 2024-01-04 | 4 | Quanterix Corp (QTRX) | Grant/award (A): 2,947 @ $0 · Grant/award (A): 6,412 (derivative) @ $0 | EDGAR |
| 2023-10-20 | 4 | STANDARD BIOTOOLS INC. (LAB) | Grant/award (A): 1,574 @ $2.54 | EDGAR |
| 2023-06-16 | 4 | STANDARD BIOTOOLS INC. (LAB) | Grant/award (A): 26,376 @ $0 · Grant/award (A): 35,380 (derivative) @ $0 | EDGAR |
| 2023-05-22 | 4 | REPLIGEN CORP (RGEN) | Grant/award (A): 686 @ $0 · Grant/award (A): 1,487 (derivative) @ $0 | EDGAR |
| 2023-05-08 | 4 | REPLIGEN CORP (RGEN) | Code (L): 11 @ $186.22 · Purchase (P): 500 @ $161.15 · Purchase (P): 500 @ $159.19 · Purchase (P): 500 @ $156.18 | EDGAR |
| 2023-02-22 | 4 | STANDARD BIOTOOLS INC. (LAB) | Grant/award (A): 29,665 @ $0 | EDGAR |
| 2023-02-08 | 4 | REPLIGEN CORP (RGEN) | Grant/award (A): 111 @ $0 · Grant/award (A): 239 (derivative) @ $0 · Grant/award (A): 1,819 (derivative) @ $0 | EDGAR |
| 2023-01-04 | 4 | Quanterix Corp (QTRX) | Grant/award (A): 8,083 @ $0 · Grant/award (A): 12,124 (derivative) @ $0 | EDGAR |
| 2022-08-10 | 4 | Quanterix Corp (QTRX) | Purchase (P): 89,667 @ $8.43 | EDGAR |
| 2022-06-17 | 4 | STANDARD BIOTOOLS INC. (LAB) | Grant/award (A): 30,914 @ $0 · Grant/award (A): 42,571 (derivative) @ $0 | EDGAR |
| 2022-04-06 | 4 | STANDARD BIOTOOLS INC. (LAB) | Grant/award (A): 15,852 @ $0 · Grant/award (A): 23,401 (derivative) @ $0 | EDGAR |
| 2022-01-05 | 4 | Quanterix Corp (QTRX) | Grant/award (A): 2,668 @ $0 · Grant/award (A): 427 @ $42.41 · Grant/award (A): 4,002 (derivative) @ $0 | EDGAR |
| 2021-10-05 | 4 | Quanterix Corp (QTRX) | Grant/award (A): 354 @ $51.18 | EDGAR |
| 2021-07-06 | 4 | Quanterix Corp (QTRX) | Grant/award (A): 304 @ $59.48 | EDGAR |
| 2021-04-02 | 4 | Quanterix Corp (QTRX) | Grant/award (A): 294 @ $61.45 | EDGAR |
| 2021-01-05 | 4 | Quanterix Corp (QTRX) | Grant/award (A): 2,270 @ $0 · Grant/award (A): 410 @ $44.11 · Grant/award (A): 7,900 (derivative) @ $0 | EDGAR |
| 2020-11-06 | 4 | Quanterix Corp (QTRX) | Option exercise (M): 1,600 @ $2.28 · Sale (S): 1,600 @ $39.40 · Option exercise (M): 1,372 @ $2.28 · Sale (S): 1,372 @ $42.45 · Option exercise (M): 1,600 (derivative) @ $0 · Option exercise (M): 1,372 (derivative) @ $0 | EDGAR |
| 2020-10-20 | 4 | Quanterix Corp (QTRX) | Option exercise (M): 1,600 @ $2.28 · Sale (S): 1,600 @ $44.59 · Option exercise (M): 1,600 @ $2.28 · Sale (S): 1,600 @ $42.57 · Option exercise (M): 1,600 (derivative) @ $0 · Option exercise (M): 1,600 (derivative) @ $0 | EDGAR |
| 2020-10-08 | 4 | Quanterix Corp (QTRX) | Option exercise (M): 1,600 @ $2.28 · Sale (S): 1,600 @ $36.47 · Option exercise (M): 1,600 @ $2.28 · Sale (S): 1,600 @ $37.17 · Option exercise (M): 1,600 (derivative) @ $0 · Option exercise (M): 1,600 (derivative) @ $0 | EDGAR |
| 2020-10-05 | 4 | Quanterix Corp (QTRX) | Grant/award (A): 520 @ $34.70 | EDGAR |
| 2020-09-30 | 4 | Quanterix Corp (QTRX) | Option exercise (M): 1,600 @ $1.93 · Sale (S): 1,600 @ $33.09 · Option exercise (M): 1,458 @ $1.93 · Sale (S): 1,458 @ $32.49 · Option exercise (M): 142 @ $2.28 · Sale (S): 142 @ $32.80 · +3 more | EDGAR |
| 2020-09-17 | 4 | Quanterix Corp (QTRX) | Option exercise (M): 1,600 @ $1.93 · Sale (S): 1,600 @ $33.16 · Option exercise (M): 1,600 @ $1.93 · Sale (S): 1,600 @ $32.43 · Option exercise (M): 907 (derivative) @ $0 · Option exercise (M): 693 (derivative) @ $0 · +1 more | EDGAR |
| 2020-09-03 | 4 | Quanterix Corp (QTRX) | Option exercise (M): 1,600 @ $1.93 · Sale (S): 1,600 @ $35.37 · Option exercise (M): 1,600 @ $1.93 · Sale (S): 1,600 @ $35.08 · Option exercise (M): 1,600 (derivative) @ $0 · Option exercise (M): 1,600 (derivative) @ $0 | EDGAR |
| 2020-08-20 | 4 | Quanterix Corp (QTRX) | Option exercise (M): 1,600 @ $1.93 · Sale (S): 1,600 @ $34.52 · Option exercise (M): 1,600 @ $1.93 · Sale (S): 1,600 @ $34.92 · Option exercise (M): 1,600 (derivative) @ $0 · Option exercise (M): 1,600 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-18 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1310268 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs